

# Maree T Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8273388/publications.pdf>

Version: 2024-02-01

175  
papers

7,577  
citations

53794

45  
h-index

62596

80  
g-index

176  
all docs

176  
docs citations

176  
times ranked

7656  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1612-1661.	6.4	13
2	Journey to the Market: The Evolution of Biodegradable Drug Delivery Systems. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 935.	2.5	16
3	Design, synthesis and evaluation of alpha lipoic acid derivatives to treat multiple sclerosis-associated central neuropathic pain. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 69, 116889.	3.0	3
4	Characterisation of a rat model of mechanical low back pain at an advanced stage using immunohistochemical methods. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 96-106.	1.9	1
5	Sustained release ketamine-loaded porous silicon-PLGA microparticles prepared by an optimized supercritical CO <sub>2</sub> process. <i>Drug Delivery and Translational Research</i> , 2021, , 1.	5.8	3
6	Assessment of the Anti-Allodynic and Anti-Hyperalgesic Efficacy of a Glycine Transporter 2 Inhibitor Relative to Pregabalin, Duloxetine and Indomethacin in a Rat Model of Cisplatin-Induced Peripheral Neuropathy. <i>Biomolecules</i> , 2021, 11, 940.	4.0	5
7	Pharmacological characterization of the chronic phase of the monoiodoacetate-induced rat model of osteoarthritis pain in the knee joint. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 1515-1522.	1.9	5
8	Optimisation of a Microfluidic Method for the Delivery of a Small Peptide. <i>Pharmaceutics</i> , 2021, 13, 1505.	4.5	3
9	Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. <i>Drug Delivery and Translational Research</i> , 2021, , 1.	5.8	0
10	Use of Microfluidics to Fabricate Bioerodable Lipid Hybrid Nanoparticles Containing Hydromorphone or Ketamine for the Relief of Intractable Pain. <i>Pharmaceutical Research</i> , 2020, 37, 211.	3.5	9
11	Assessment of the anti-hyperalgesic efficacy of J-156, relative to clinically available analgesic/adjuvant agents in a rat model of mild to moderate chronic mechanical low back pain (LBP). <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1912-1922.	1.9	1
12	Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain. <i>Pharmacological Reports</i> , 2020, 72, 1418-1425.	3.3	5
13	Comparative studies of glial fibrillary acidic protein and brain-derived neurotrophic factor expression in two transgenic mouse models of Alzheimer's disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1740-1750.	1.9	0
14	In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the $\mu$ -arrestin2 recruitment assay: No two ligands have the same profile. <i>European Journal of Pharmacology</i> , 2020, 872, 172947.	3.5	8
15	Intracerebroventricular administration of CYX-6, a potent $\mu$ -opioid receptor agonist, a $\delta$ - and $\kappa$ -opioid receptor antagonist and a biased ligand at $\mu$ , $\delta$ & $\kappa$ -opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine. <i>European Journal of Pharmacology</i> , 2020, 871, 172918.	3.5	12
16	Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation. <i>International Journal of Pharmaceutics</i> , 2020, 581, 119291.	5.2	36
17	Countering opioid-induced respiratory depression by non-opioids that are respiratory stimulants. <i>F1000Research</i> , 2020, 9, 91.	1.6	24
18	Transcriptomic characterisation of the optimised rat model of Walker 256 breast cancer cell-induced bone pain. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 1201-1215.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Cyclooctatetraene: A Bioactive Cubane Paradigm Complement. <i>Chemistry - A European Journal</i> , 2019, 25, 2729-2734.	3.3	24
20	Study Protocol for a Pilot, Open-Label, Prospective, and Observational Study to Evaluate the Pharmacokinetics of Drugs Administered to Patients during Extracorporeal Circulation; Potential of In Vivo Cytochrome P450 Phenotyping to Optimise Pharmacotherapy. <i>Methods and Protocols</i> , 2019, 2, 38.	2.0	0
21	The cubane paradigm in bioactive molecule discovery: further scope, limitations and the cyclooctatetraene complement. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 6790-6798.	2.8	49
22	J-2156, a somatostatin receptor type 4 agonist, alleviates mechanical hyperalgesia in a rat model of chronic low back pain. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109056.	5.6	8
23	Bioerodable Ketamine-Loaded Microparticles Fabricated Using Dissolvable Hydrogel Template Technology. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1220-1226.	3.3	7
24	Nitric oxide modulates $\mu$ -opioid receptor function in vitro. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 676-685.	1.9	5
25	Synthesis and Biological Evaluation of Fentanyl Analogues Modified at Phenyl Groups with Alkyls. <i>ACS Chemical Neuroscience</i> , 2019, 10, 201-208.	3.5	8
26	Establishment and characterisation of a stavudine (d4T)-induced rat model of antiretroviral toxic neuropathy (ATN) using behavioural and pharmacological methods. <i>Inflammopharmacology</i> , 2019, 27, 387-396.	3.9	2
27	Sustained-Release Hydromorphone Microparticles Produced by Supercritical Fluid Polymer Encapsulation. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 811-814.	3.3	13
28	Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. <i>Neuropharmacology</i> , 2018, 131, 238-255.	4.1	97
29	Effect of cardiopulmonary bypass on cytochrome P450 enzyme activity: implications for pharmacotherapy. <i>Drug Metabolism Reviews</i> , 2018, 50, 109-124.	3.6	2
30	Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain. <i>Inflammopharmacology</i> , 2018, 26, 77-86.	3.9	62
31	Morphine hyposensitivity in streptozotocin-diabetic rats: Reversal by dietary arginine treatment. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 42-49.	1.9	6
32	An improved liquid chromatography tandem mass spectrometry (LC-MS/MS) method for quantification of dexmedetomidine concentrations in samples of human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1073, 118-122.	2.3	6
33	Inhibition of acid-sensing ion channels by diminazene and APETx2 evoke partial and highly variable antihyperalgesia in a rat model of inflammatory pain. <i>British Journal of Pharmacology</i> , 2018, 175, 2204-2218.	5.4	39
34	Effects of long-term opioid analgesics on cognitive performance and plasma cytokine concentrations in patients with chronic low back pain: a cross-sectional pilot study. <i>Pain Reports</i> , 2018, 3, e669.	2.7	26
35	Formulation of Bioerodible Ketamine Microparticles as an Analgesic Adjuvant Treatment Produced by Supercritical Fluid Polymer Encapsulation. <i>Pharmaceutics</i> , 2018, 10, 264.	4.5	8
36	An improved LC-MS/MS method for simultaneous evaluation of CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activity. <i>Bioanalysis</i> , 2018, 10, 1577-1590.	1.5	5

#	ARTICLE	IF	CITATIONS
37	In vivo profiling of four centrally administered opioids for antinociception, constipation and respiratory depression: Between-colony differences in Sprague Dawley rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 1056-1066.	1.9	5
38	Comparative analgesic efficacy of pregabalin administered according to either a prevention protocol or an intervention protocol in rats with cisplatin-induced peripheral neuropathy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 1067-1075.	1.9	8
39	Chronic low back pain: a mini-review on pharmacological management and pathophysiological insights from clinical and pre-clinical data. <i>Inflammopharmacology</i> , 2018, 26, 881-898.	3.9	19
40	The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain. <i>Frontiers in Pharmacology</i> , 2018, 9, 495.	3.5	17
41	Optimization and In Vivo Profiling of a Refined Rat Model of Walker 256 Breast Cancer Cell-Induced Bone Pain Using Behavioral, Radiological, Histological, Immunohistochemical and Pharmacological Methods. <i>Frontiers in Pharmacology</i> , 2017, 8, 442.	3.5	15
42	Establishment and Characterization of a Novel Rat Model of Mechanical Low Back Pain Using Behavioral, Pharmacologic and Histologic Methods. <i>Frontiers in Pharmacology</i> , 2017, 8, 493.	3.5	14
43	Attenuation of the Infiltration of Angiotensin II Expressing CD3+ T-Cells and the Modulation of Nerve Growth Factor in Lumbar Dorsal Root Ganglia – A Possible Mechanism Underpinning Analgesia Produced by EMA300, An Angiotensin II Type 2 (AT2) Receptor Antagonist. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 389.	2.9	16
44	Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 88.	2.0	27
45	Evaluation of a High-Throughput Peptide Reactivity Format Assay for Assessment of the Skin Sensitization Potential of Chemicals. <i>Frontiers in Pharmacology</i> , 2016, 7, 53.	3.5	10
46	Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading. <i>Frontiers in Pharmacology</i> , 2016, 7, 185.	3.5	255
47	The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats. <i>Frontiers in Pharmacology</i> , 2016, 7, 286.	3.5	38
48	The effect of 1Âmg folic acid supplementation on clinical outcomes in female migraine with aura patients. <i>Journal of Headache and Pain</i> , 2016, 17, 60.	6.0	29
49	Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. <i>Angewandte Chemie</i> , 2016, 128, 3644-3649.	2.0	34
50	Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 3580-3585.	13.8	126
51	Frontispiece: Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. <i>Angewandte Chemie - International Edition</i> , 2016, 55, .	13.8	1
52	Frontispiz: Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. <i>Angewandte Chemie</i> , 2016, 128, .	2.0	0
53	<i>In Vitro</i> Metabolic Stability and <i>In Vivo</i> Biodistribution of 3-Methyl-4-furoxancarbaldehyde Using PET Imaging in Rats. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 563-567.	2.8	11
54	High-throughput assay for quantification of the plasma concentrations of thiopental using automated solid phase extraction (SPE) directly coupled to LC-MS/MS instrumentation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1038, 80-87.	2.3	6

#	ARTICLE	IF	CITATIONS
55	Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain. <i>Pain</i> , 2016, 157, S33-S41.	4.2	42
56	Antiallodynic effects of alpha lipoic acid in an optimized <sc>RR</sc>â€<sc>EAE</sc> mouse model of <sc>MS</sc>â€neuropathic pain are accompanied by attenuation of upregulated <sc>BDNF</sc>â€<sc>ERK</sc> signaling in the dorsal horn of the spinal cord. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00137.	2.4	32
57	Neurotrophins and Neuropathic Pain: Role in Pathobiology. <i>Molecules</i> , 2015, 20, 10657-10688.	3.8	145
58	In vivo High Angular Resolution Diffusion-Weighted Imaging of Mouse Brain at 16.4 Tesla. <i>PLoS ONE</i> , 2015, 10, e0130133.	2.5	32
59	In vitro methods for hazard assessment of industrial chemicals â€“ opportunities and challenges. <i>Frontiers in Pharmacology</i> , 2015, 6, 94.	3.5	20
60	The furoxan nitric oxide donor, <sc>PRG</sc>150, evokes doseâ€dependent analgesia in a rat model of painful diabetic neuropathy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 921-929.	1.9	14
61	Angiotensin II Type 2â€Receptor: New Clinically Validated Target in the Treatment of Neuropathic Pain. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 128-130.	4.7	13
62	A novel fully validated LCâ€MS/MS method for quantification of pyridoxal-5â€phosphate concentrations in samples of human whole blood. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1000, 77-83.	2.3	9
63	Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 25-35.	3.4	32
64	Topical Application of a Novel Oxycodone Gel Formulation (Tocopheryl Phosphate Mixture) in a Rat Model of Peripheral Inflammatory Pain Produces Localized Pain Relief Without Significant Systemic Exposure. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2388-2396.	3.3	14
65	Novel Polymeric Bioerodable Microparticles for Prolonged-Release Intrathecal Delivery of Analgesic Agents for Relief of Intractable Cancer-Related Pain. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2334-2344.	3.3	23
66	<i>In vivo</i> profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. <i>British Journal of Pharmacology</i> , 2015, 172, 532-548.	5.4	57
67	Current developments in MRI for assessing rodent models of multiple sclerosis. <i>Future Neurology</i> , 2014, 9, 487-511.	0.5	1
68	Analgesic Efficacy and Mode of Action of a Selective Small Molecule Angiotensin II Type 2 Receptor Antagonist in a Rat Model of Prostate Cancer-Induced Bone Pain. <i>Pain Medicine</i> , 2014, 15, 93-110.	1.9	45
69	Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic pain. <i>Behavioural Pharmacology</i> , 2014, 25, 732-740.	1.7	32
70	Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy. <i>Behavioural Pharmacology</i> , 2014, 25, 137-146.	1.7	23
71	Endomorphin analogues with mixed $\mu$ -opioid (MOP) receptor agonism/ $\kappa$ -opioid (DOP) receptor antagonism and lacking $\beta$ -arrestin2 recruitment activity. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2208-2219.	3.0	12
72	Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. <i>Inflammopharmacology</i> , 2014, 22, 1-22.	3.9	98

#	ARTICLE	IF	CITATIONS
73	Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 798-806.	1.9	31
74	Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 126, 13-27.	2.9	34
75	Fully validated LC-MS/MS method for quantification of homocysteine concentrations in samples of human serum: A new approach. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 972, 14-21.	2.3	21
76	Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: A mini review. <i>Journal of Neuroscience Methods</i> , 2014, 233, 166-171.	2.5	23
77	Peripherally acting novel lipo-endorphin-1 peptides in neuropathic pain without producing constipation. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 1898-1904.	3.0	17
78	Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. <i>Inflammopharmacology</i> , 2013, 21, 339-363.	3.9	38
79	Comment on "Protective arms of the renin-angiotensin system in neurological disease". <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 838-838.	1.9	0
80	Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 106, 33-46.	2.9	26
81	The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. <i>BMC Anesthesiology</i> , 2013, 13, 7.	1.8	38
82	Small Molecule Angiotensin II Type 2 Receptor (AT <sub>2</sub> R) Antagonists as Novel Analgesics for Neuropathic Pain: Comparative Pharmacokinetics, Radioligand Binding, and Efficacy in Rats. <i>Pain Medicine</i> , 2013, 14, 692-705.	1.9	79
83	A Small Molecule Angiotensin II Type 2 Receptor (AT <sub>2</sub> R) Antagonist Produces Analgesia in a Rat Model of Neuropathic Pain by Inhibition of p38 Mitogen-Activated Protein Kinase (MAPK) and p44/p42 MAPK Activation in the Dorsal Root Ganglia. <i>Pain Medicine</i> , 2013, 14, 1557-1568.	1.9	66
84	Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 726-727.	3.0	42
85	Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). <i>Frontiers in Pharmacology</i> , 2013, 4, 156.	3.5	204
86	Pregabalin for the treatment of fibromyalgia. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1527-1533.	1.8	19
87	Pharmacogenetics of pain and analgesia. <i>Clinical Genetics</i> , 2012, 82, 321-330.	2.0	31
88	Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. <i>Critical Care</i> , 2012, 16, R194.	5.8	233
89	Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 881-882, 34-41.	2.3	21
90	ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. <i>BMC Anesthesiology</i> , 2012, 12, 29.	1.8	90

#	ARTICLE	IF	CITATIONS
91	High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 903, 126-133.	2.3	51
92	Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. <i>Journal of Critical Care</i> , 2012, 27, 741.e9-741.e18.	2.2	257
93	Synthesis and Biological Evaluation of an Orally Active Glycosylated Endomorphin-1. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5859-5867.	6.4	72
94	Lipo-Endomorphin-1 Derivatives with Systemic Activity against Neuropathic Pain without Producing Constipation. <i>PLoS ONE</i> , 2012, 7, e41909.	2.5	29
95	Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2012, 14, 105-11.	0.1	19
96	Pain, analgesia and genetics. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 1387-1400.	2.4	43
97	Longitudinal Study of Painful Diabetic Neuropathy in the Zucker Diabetic Fatty Rat Model of Type 2 Diabetes: Impaired Basal G-Protein Activity Appears to Underpin Marked Morphine Hyposensitivity at 6 Months. <i>Pain Medicine</i> , 2011, 12, 437-450.	1.9	26
98	Insulin Implants Prevent the Temporal Development of Mechanical Allodynia and Opioid Hyposensitivity for 24-Weeks in Streptozotocin (STZ)-Diabetic Wistar Rats. <i>Pain Medicine</i> , 2011, 12, 782-793.	1.9	13
99	PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. <i>British Journal of Cancer</i> , 2011, 104, 635-642.	6.4	154
100	Pregabalin in severe burn injury pain: A double-blind, randomised placebo-controlled trial. <i>Pain</i> , 2011, 152, 1279-1288.	4.2	74
101	Preliminary Study of the Plasma and Cerebrospinal Fluid Concentrations of IL-6 and IL-10 in Patients with Chronic Pain Receiving Intrathecal Opioid Infusions by Chronically Implanted Pump for Pain Management. <i>Pain Medicine</i> , 2010, 11, 550-561.	1.9	29
102	A Randomized, Controlled Trial of Oxycodone Versus Placebo in Patients With PostHerpetic Neuralgia and Painful Diabetic Neuropathy Treated With Pregabalin. <i>Journal of Pain</i> , 2010, 11, 462-471.	1.4	85
103	Comparative studies of the neuro-excitatory behavioural effects of morphine-3-glucuronide and dynorphin A(2-17) following spinal and supraspinal routes of administration. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 93, 498-505.	2.9	15
104	ANTINOCICEPTION VERSUS SERUM CONCENTRATION RELATIONSHIPS FOLLOWING ACUTE ADMINISTRATION OF INTRAVENOUS MORPHINE IN MALE AND FEMALE SPRAGUE-DAWLEY RATS: DIFFERENCES BETWEEN THE TAIL FLICK AND HOT PLATE NOCICEPTIVE TESTS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2009, 36, 20-28.	1.9	29
105	Ï-Connopptide Pharmacophore Development: Toward a Novel Class of Norepinephrine Transporter Inhibitor (Xen2174) for Pain. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6991-7002.	6.4	70
106	SEX DIFFERENCES IN THE PHARMACOKINETICS, OXIDATIVE METABOLISM AND ORAL BIOAVAILABILITY OF OXYCODONE IN THE SPRAGUE-DAWLEY RAT. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 295-302.	1.9	46
107	An Update on the Pharmacological Management of Post-Herpetic Neuralgia and Painful Diabetic Neuropathy. <i>CNS Drugs</i> , 2008, 22, 417-442.	5.9	97
108	Differences between and combinations of opioids re-visited. <i>Current Opinion in Anaesthesiology</i> , 2008, 21, 596-601.	2.0	34

#	ARTICLE	IF	CITATIONS
109	Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain. <i>Pain</i> , 2007, 132, 289-300.	4.2	149
110	Studies on neurosteroids XIX. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 848, 188-199.	2.3	45
111	Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatographyâ€“electrospray ionizationâ€“tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 848, 264-270.	2.3	22
112	STUDIES WITH KETAMINE AND ALFENTANIL FOLLOWING FREUND'S COMPLETE ADJUVANT-INDUCED INFLAMMATION IN RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 414-420.	1.9	5
113	Oxycodoneâ€™s Mechanism of Action and Potency Differences after Spinal and Systemic Routes of Administration. <i>Anesthesiology</i> , 2007, 106, 1063-1064.	2.5	7
114	Simultaneous determination of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone concentrations in rat serum by high performance liquid chromatographyâ€“electrospray ionizationâ€“tandem mass spectrometry†. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 814, 241-249.	2.3	36
115	Co-administration of oxycodone and morphine and analgesic synergy re-examined. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 486-487.	2.4	6
116	Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 524-535.	2.4	25
117	Comparison of the Pharmacokinetics of Oxycodone and Noroxycodone in Male Dark Agouti and Spragueâ€™Dawley Rats: Influence of Streptozotocin-Induced Diabetes. <i>Pharmaceutical Research</i> , 2005, 22, 1489-1498.	3.5	22
118	Anti-allodynic efficacy of the Î±-conopeptide, Xen2174, in rats with neuropathic pain. <i>Pain</i> , 2005, 118, 112-124.	4.2	78
119	Measurement of intracellular Ca <sup>2+</sup> in cultured rat embryonic hippocampal neurons using a fluorescence microplate reader: potential application to biomolecular screening. <i>Journal of Pharmacological and Toxicological Methods</i> , 2004, 49, 81-87.	0.7	21
120	Deletion of guanine nucleotide binding protein Î± subunit in mice induces a gene dose dependent tolerance to morphine. <i>Neuropharmacology</i> , 2004, 46, 836-846.	4.1	26
121	The Neuroexcitatory Morphine Metabolite, Morphine-3-glucuronide (M3G), is not Neurotoxic in Primary Cultures of either Hippocampal or Cerebellar Granule Neurones. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2003, 93, 197-200.	0.0	3
122	The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. <i>Heart Lung and Circulation</i> , 2003, 12, 44-50.	0.4	173
123	Morphine-3-Glucuronideâ€™s Neuro-Excitatory Effects Are Mediated via Indirect Activation of N-Methyl-d-Aspartic Acid Receptors: Mechanistic Studies in Embryonic Cultured Hippocampal Neurones. <i>Anesthesia and Analgesia</i> , 2003, 97, 494-505.	2.2	61
124	The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. <i>Pain</i> , 2002, 96, 119-127.	4.2	155
125	A simple, low-cost, remote fiber-optic micro volume fluorescence flowcell for capillary flow-injection analysis. <i>Analytical and Bioanalytical Chemistry</i> , 2002, 374, 385-389.	3.7	12
126	Hydromorphone-3-glucuronide. <i>Life Sciences</i> , 2001, 69, 409-420.	4.3	119



#	ARTICLE	IF	CITATIONS
127	Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 693-698.	2.4	33
128	Sensory changes during the ovulatory phase of the menstrual cycle in healthy women. <i>European Journal of Pain</i> , 2001, 5, 135-144.	2.8	65
129	Oxycodone has a distinctly different pharmacology from morphine. <i>European Journal of Pain</i> , 2001, 5, 135-136.	2.8	8
130	The role of morphine-6-glucuronide (M6G) in pain control. <i>Pain Reviews</i> , 2001, 8, 171-191.	0.0	6
131	Neuroexcitatory Effects Of Morphine And Hydromorphone: Evidence Implicating The 3-Glucuronide Metabolites. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2000, 27, 524-528.	1.9	255
132	Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. <i>Pain</i> , 2000, 84, 421-428.	4.2	75
133	Brain region-specific studies of the excitatory behavioral effects of morphine-3-glucuronide. <i>Life Sciences</i> , 1999, 65, 225-236.	4.3	27
134	Cerebrospinal Fluid and Plasma Concentrations of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Patients Before and After Initiation of Intracerebroventricular Morphine for Cancer Pain Management. <i>Anesthesia and Analgesia</i> , 1999, 88, 109-116.	2.2	9
135	Intraarticular and Periarticular Opioid Binding in Inflamed Tissue in Experimental Canine Arthritis. <i>Anesthesia and Analgesia</i> , 1999, 89, 409-415.	2.2	17
136	Cerebrospinal Fluid and Plasma Concentrations of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Patients Before and After Initiation of Intracerebroventricular Morphine for Cancer Pain Management. <i>Anesthesia and Analgesia</i> , 1999, 88, 109-116.	2.2	34
137	Intraarticular and Periarticular Opioid Binding in Inflamed Tissue in Experimental Canine Arthritis. <i>Anesthesia and Analgesia</i> , 1999, 89, 409-415.	2.2	42
138	Solid-phase extraction method with high-performance liquid chromatography and electrochemical detection for the quantitative analysis of oxycodone in human plasma. <i>Biomedical Applications</i> , 1998, 712, 169-175.	1.7	22
139	Investigation of the antinociceptive efficacy and relative potency of extended duration injectable 3-acylmorphine-6-sulfate prodrugs in rats. <i>International Journal of Pharmaceutics</i> , 1998, 163, 191-201.	5.2	9
140	Hydromorphone-3-glucuronide: Biochemical synthesis and preliminary pharmacological evaluation. <i>Life Sciences</i> , 1998, 63, 401-411.	4.3	49
141	Clinical Pharmacology and Adverse Effects. , 1998, , 188-211.		1
142	Improved One-Step Solid-Phase Extraction Method for Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide From Plasma and Quantitation Using High-Performance Liquid Chromatography With Electrochemical Detection. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 215-218.	2.0	8
143	Morphine has a Dual Concentration-dependent Effect on K <sup>+</sup> -evoked Substance P Release from Rat Peripheral Airways. <i>Pulmonary Pharmacology and Therapeutics</i> , 1997, 10, 215-221.	2.6	14
144	Biochemical synthesis, purification and preliminary pharmacological evaluation of normorphine-3-glucuronide. <i>Life Sciences</i> , 1997, 61, 95-104.	4.3	7

#	ARTICLE	IF	CITATIONS
145	The intrinsic antinociceptive effects of oxycodone appear to be $\mu$ -opioid receptor mediated. <i>Pain</i> , 1997, 73, 151-157.	4.2	228
146	Quantitative autoradiography of peripheral opioid binding sites in rat lung. <i>European Journal of Pharmacology</i> , 1996, 310, 47-53.	3.5	25
147	Pharmacokinetics and Pharmacodynamics of Oxycodone When Given Intravenously and Rectally to Adult Patients with Cancer Pain. <i>Anesthesia and Analgesia</i> , 1995, 80, 296-302.	2.2	1
148	Pharmacokinetics and Pharmacodynamics of Oxycodone When Given Intravenously and Rectally to Adult Patients with Cancer Pain. <i>Anesthesia and Analgesia</i> , 1995, 80, 296-302.	2.2	87
149	Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. <i>Pain</i> , 1995, 62, 51-60.	4.2	107
150	Effects of morphine-3-glucuronide and morphine on the K <sup>+</sup> -evoked release of [3H]-glutamic acid and [14C]-gamma-aminobutyric acid from rat brain synaptosomes. <i>Life Sciences</i> , 1995, 58, 447-454.	4.3	13
151	Characterization of non-conventional opioid binding sites in rat and human lung. <i>European Journal of Pharmacology</i> , 1994, 268, 247-255.	2.6	47
152	Pharmacology of Morphine and Morphine-3-glucuronide at Opioid, Excitatory Amino Acid, GABA and Glycine Binding Sites. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1994, 75, 73-81.	0.0	62
153	Comments on Goucke et al., <i>Pain</i> , 56 (1994) 145-149. <i>Pain</i> , 1994, 59, 155-156.	4.2	0
154	The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. <i>Life Sciences</i> , 1994, 54, 687-694.	4.3	91
155	The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. <i>Life Sciences</i> , 1994, 54, 1229-1236.	4.3	46
156	Quantitation of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Plasma and Cerebrospinal Fluid Using Solid-Phase Extraction and High-Performance Liquid Chromatography with Electrochemical Detection. <i>Therapeutic Drug Monitoring</i> , 1994, 16, 200-208.	2.0	55
157	Determination of the Serum Protein Binding of Oxycodone and Morphine Using Ultrafiltration. <i>Therapeutic Drug Monitoring</i> , 1993, 15, 440-447.	2.0	45
158	Comparative Oxycodone Pharmacokinetics in Humans After Intravenous, Oral, and Rectal Administration. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 479-484.	2.0	75
159	Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 487-495.	4.7	136
160	Quantitation of Oxycodone in Human Plasma Using High-Performance Liquid Chromatography with Electrochemical Detection. <i>Therapeutic Drug Monitoring</i> , 1991, 13, 126-130.	2.0	27
161	Dose-dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 516-524.	4.7	99
162	Morphine-3-glucuronide - a potent antagonist of morphine analgesia. <i>Life Sciences</i> , 1990, 47, 579-585.	4.3	307

#	ARTICLE	IF	CITATIONS
163	Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. <i>European Journal of Clinical Pharmacology</i> , 1986, 31, 177-182.	1.9	44
164	Simple and Reliable Determination of Bromazepam in Human Plasma by High-Performance Liquid Chromatography. <i>Analytica Chimica Acta</i> , 1985, 177, 267-271.	5.4	8
165	A Sensitive Liquid Chromatographic Assay for Plasma Aspirin and Salicylate Concentrations After Low Doses of Aspirin. <i>Therapeutic Drug Monitoring</i> , 1985, 7, 216-221.	2.0	26
166	Pharmacokinetics of midazolam in the aged. <i>European Journal of Clinical Pharmacology</i> , 1984, 26, 381-388.	1.9	58
167	Bioavailability and pharmacokinetics of phenytoin during pregnancy. <i>European Journal of Clinical Pharmacology</i> , 1984, 27, 105-110.	1.9	19
168	Metabolism of propranolol in the human maternal-placental-foetal unit. <i>European Journal of Clinical Pharmacology</i> , 1983, 24, 727-732.	1.9	14
169	Chronic propranolol administration during pregnancy. <i>European Journal of Clinical Pharmacology</i> , 1983, 25, 481-490.	1.9	12
170	Propranolol in Pregnancy Three Year Prospective Study. <i>Clinical and Experimental Hypertension Part B, Hypertension in Pregnancy</i> , 1983, 2, 341-350.	0.2	23
171	Propranolol, Propranolol Glucuronide, and Naphthoxylactic Acid in Breast Milk and Plasma. <i>Therapeutic Drug Monitoring</i> , 1983, 5, 87-94.	2.0	41
172	Novel Source of Ubiquitous Phthalates as Analytical Contaminant. <i>Journal of Pharmaceutical Sciences</i> , 1981, 70, 346-347.	3.3	3
173	The unsteady model. <i>European Journal of Clinical Pharmacology</i> , 1981, 20, 387-398.	1.9	5
174	The pharmacokinetics of midazolam in man. <i>European Journal of Clinical Pharmacology</i> , 1981, 19, 271-278.	1.9	266
175	Pharmacokinetics of prazepam in man. <i>European Journal of Clinical Pharmacology</i> , 1979, 16, 141-147.	1.9	17